Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17465
Country/Region: Eswatini
Year: 2017
Main Partner: John Snow, Inc
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USAID
Total Funding: $3,460,768 Additional Pipeline Funding: $2,701,836

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $938,560
Care: TB/HIV (HVTB) $328,154
Care: Pediatric Care and Support (PDCS) $124,081
Health Systems Strengthening (OHSS) $80,313
Testing: HIV Testing and Counseling (HVCT) $807,989
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $28,908
Treatment: Adult Treatment (HTXS) $984,513
Treatment: Pediatric Treatment (PDTX) $168,250
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2018 24
GEND_GBV <10, Female, Physical and/or Emotional Violence 2018 60
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2018 4
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2018 13
GEND_GBV <10, Male, Physical and/or Emotional Violence 2018 2
GEND_GBV <10, Male, Physical and/or Emotional Violence 2018 9
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2018 1
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 60
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 147
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 22
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 52
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 8
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 18
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 5
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 85
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 206
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 29
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 70
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 4
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 293
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 678
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 106
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 240
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 100
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 226
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 31
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 76
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 16
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 47
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 2
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 9
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 12
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 2
GEND_GBV 25-49, Male, Sexual Violence (Post-Rape Care) 2018 1
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2018 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 186
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 427
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 631
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 1,422
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 209
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 478
GEND_GBV Number of people receiving post-GBV care 2018 843
GEND_GBV Number of people receiving post-GBV care 2018 1,905
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 4,008
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 114,394
HTS_TST Service Delivery Point (Facility) ANC: <1, Negative 2018 61
HTS_TST Service Delivery Point (Facility) ANC: 1-9, Negative 2018 7
HTS_TST Service Delivery Point (Facility) ANC: 1-9, Negative 2018 223
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2018 17
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2018 540
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2018 31
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2018 1,013
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2018 78
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2018 2,296
HTS_TST Service Delivery Point (Facility) ANC: 25-49, Negative 2018 118
HTS_TST Service Delivery Point (Facility) ANC: 25-49, Negative 2018 3,365
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2018 2
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2018 2
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2018 99
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2018 10
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2018 380
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2018 21
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2018 754
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2018 5
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2018 153
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 10
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 354
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 40
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 1,355
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 21
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 757
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 97
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 3,109
HTS_TST Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 31
HTS_TST Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 1,078
HTS_TST Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 138
HTS_TST Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 4,614
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2018 21
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2018 84
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2018 168
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2018 34
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2018 77
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2018 301
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2018 168
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2018 689
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative 2018 236
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative 2018 1,022
HTS_TST Service Delivery Point (Facility) Other PITC: <1, Negative 2018 17
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 74
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 1,862
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 143
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 3,669
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 27
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 758
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 69
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 1,804
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 262
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 6,941
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 142
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 3,889
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 598
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 15,949
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 204
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 5,436
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 891
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 23,685
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2018 305
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2018 9,454
HTS_TST Service Delivery Point (Facility) TB: <1, Negative 2018 17
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2018 2
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2018 88
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2018 6
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2018 184
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2018 30
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 2
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 83
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2018 10
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2018 329
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 6
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 184
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 26
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 750
HTS_TST Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 8
HTS_TST Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 255
HTS_TST Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 38
HTS_TST Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 1,117
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2018 61
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 7
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 217
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 15
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 436
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 2
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 88
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 7
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 206
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 27
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 783
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 15
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 436
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 69
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 1,801
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 21
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 614
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 106
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 2,667
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2018 504
HTS_TST Sum of Test Result disaggregates 2018 259
HTS_TST Sum of Test Result disaggregates 2018 10,264
HTS_TST_POS By Test Result: Positive 2018 259
HTS_TST_POS By Test Result: Positive 2018 10,264
HTS_TST_POS Service Delivery Point (Facility) ANC: <1, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) ANC: 1-9, Positive 2018 23
HTS_TST_POS Service Delivery Point (Facility) ANC: 10-14, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) ANC: 10-14, Positive 2018 71
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2018 144
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2018 10
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2018 322
HTS_TST_POS Service Delivery Point (Facility) ANC: 25-49, Positive 2018 15
HTS_TST_POS Service Delivery Point (Facility) ANC: 25-49, Positive 2018 471
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2018 28
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2018 88
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2018 167
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2018 40
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2018 103
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2018 396
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 220
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2018 21
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2018 907
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 320
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 32
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 1,385
HTS_TST_POS Service Delivery Point (Facility) Inpatient: <1, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2018 27
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2018 62
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive 2018 21
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive 2018 92
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2018 26
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 121
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2018 248
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2018 40
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 59
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 233
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 134
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 17
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 539
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 413
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 26
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 1,856
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2018 98
HTS_TST_POS Service Delivery Point (Facility) TB: <1, Positive 2018 10
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2018 46
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2018 97
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2018 69
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2018 44
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2018 22
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2018 114
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 30
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 167
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2018 20
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2018 53
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2018 20
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2018 108
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2018 64
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 240
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 18
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 99
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 13
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 364
PMTCT_ART Already on ART at beginning of current pregnancy 2018 317
PMTCT_ART Already on ART at beginning of current pregnancy 2018 2,174
PMTCT_ART New on ART 2018 135
PMTCT_ART New on ART 2018 921
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 452
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 3,095
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 1,434
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 9,128
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 344
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 3,144
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 34
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 288
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 283
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 2,608
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 9
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 10
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 91
PMTCT_EID Unknown, <= 2 months 2018 17
PMTCT_EID Unknown, <= 2 months 2018 140
PMTCT_EID Unknown, 2 - 12 months 2018 8
PMTCT_STAT By Age (Numerator): : 15-19 2018 212
PMTCT_STAT By Age (Numerator): 10-14 2018 391
PMTCT_STAT By Age (Numerator): 10-14 2018 56
PMTCT_STAT By Age (Numerator): 15-19 2018 1,466
PMTCT_STAT By Age (Numerator): 20-24 2018 2,061
PMTCT_STAT By Age (Numerator): 20-24 2018 354
PMTCT_STAT By Age (Numerator): 25-49 2018 5,182
PMTCT_STAT By Age (Numerator): 25-49 2018 711
PMTCT_STAT By Age (Numerator): 50+ 2018 5
PMTCT_STAT By Age (Numerator): 50+ 2018 100
PMTCT_STAT By known positives: 10-14 2018 9
PMTCT_STAT By known positives: 15-19 2018 56
PMTCT_STAT By known positives: 20-24 2018 73
PMTCT_STAT By known positives: 25-49 2018 191
PMTCT_STAT By known positives: 50+ 2018 16
PMTCT_STAT By new negatives: 10-14 2018 46
PMTCT_STAT By new negatives: 15-19 2018 136
PMTCT_STAT By new negatives: 20-24 2018 200
PMTCT_STAT By new negatives: 25-49 2018 435
PMTCT_STAT By new negatives: 50+ 2018 81
PMTCT_STAT By new positives: 10-14 2018 1
PMTCT_STAT By new positives: 15-19 2018 21
PMTCT_STAT By new positives: 20-24 2018 29
PMTCT_STAT By new positives: 25-49 2018 85
PMTCT_STAT By new positives: 50+ 2018 7
PMTCT_STAT By Number of known positives: 10-14 2018 78
PMTCT_STAT By Number of known positives: 15-19 2018 375
PMTCT_STAT By Number of known positives: 20-24 2018 499
PMTCT_STAT By Number of known positives: 25-49 2018 1,227
PMTCT_STAT By Number of new negative: 10-14 2018 313
PMTCT_STAT By Number of new negative: 15-19 2018 945
PMTCT_STAT By Number of new negative: 20-24 2018 1,370
PMTCT_STAT By Number of new negative: 25-49 2018 3,376
PMTCT_STAT By Number of new negative: 50+ 2018 3
PMTCT_STAT By Number of new positives: 15-19 2018 141
PMTCT_STAT By Number of new positives: 20-24 2018 188
PMTCT_STAT By Number of new positives: 25-49 2018 567
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 1,434
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 9,128
PMTCT_STAT_den By Age (Denominator): <15-19 2018 1,543
PMTCT_STAT_den By Age (Denominator): 10-14 2018 63
PMTCT_STAT_den By Age (Denominator): 10-14 2018 410
PMTCT_STAT_den By Age (Denominator): 15-19 2018 232
PMTCT_STAT_den By Age (Denominator): 20-24 2018 323
PMTCT_STAT_den By Age (Denominator): 20-24 2018 2,154
PMTCT_STAT_den By Age (Denominator): 25-49 2018 813
PMTCT_STAT_den By Age (Denominator): 25-49 2018 5,449
PMTCT_STAT_den By Age (Denominator): 50+ 2018 110
PMTCT_STAT_den By Age (Denominator): 50+ 2018 6
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 18
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 3
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 590
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 11
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 8
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 772
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 11
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 1,391
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 11
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 1,391
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 18
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 3
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 594
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 5
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 8
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 774
TB_PREV By Age/Sex (Numerator): <15, Female 2018 116
TB_PREV By Age/Sex (Numerator): <15, Female 2018 1,725
TB_PREV By Age/Sex (Numerator): <15, Male 2018 162
TB_PREV By Age/Sex (Numerator): <15, Male 2018 1,479
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 856
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 35,299
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 582
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 16,963
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 1,548
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 49,912
TB_PREV By Therapy type (Numerator): Alternative Regimen 2018 84
TB_PREV By Therapy type (Numerator): Alternative Regimen 2018 2,777
TB_PREV By Therapy type (Numerator): Continuous IPT 2018 84
TB_PREV By Therapy type (Numerator): Continuous IPT 2018 2,777
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 1,716
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 55,466
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 2,016
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 65,250
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 136
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 2,029
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 188
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 1,739
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 1,007
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 41,525
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 685
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 19,957
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 1,812
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 58,720
TB_PREV_den By Therapy type (Denominator): Alternative Regimen 2018 3,265
TB_PREV_den By Therapy type (Denominator): Continuous IPT 2018 3,265
TB_PREV_den By Therapy type (Denominator):Alternative Regimen 2018 102
TB_PREV_den By Therapy type (Denominator):Continuous IPT 2018 102
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 40
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 5
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 682
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 32
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 19
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 910
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 24
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 1,664
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 24
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 1,714
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 41
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 5
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 703
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 32
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 19
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 938
TX_CURR Age/Sex: <1 2018 37
TX_CURR Age/Sex: <1 2018 627
TX_CURR Age/Sex: <1-9 2018 2,329
TX_CURR Age/Sex: 1-9 2018 180
TX_CURR Age/Sex: 10-14 Female 2018 52
TX_CURR Age/Sex: 10-14 Female 2018 556
TX_CURR Age/Sex: 10-14 Male 2018 68
TX_CURR Age/Sex: 10-14 Male 2018 449
TX_CURR Age/Sex: 15-19 Female 2018 48
TX_CURR Age/Sex: 15-19 Female 2018 1,774
TX_CURR Age/Sex: 15-19 Male 2018 19
TX_CURR Age/Sex: 15-19 Male 2018 247
TX_CURR Age/Sex: 20-24 Female 2018 150
TX_CURR Age/Sex: 20-24 Female 2018 7,149
TX_CURR Age/Sex: 20-24 Male 2018 25
TX_CURR Age/Sex: 20-24 Male 2018 780
TX_CURR Age/Sex: 25-49 Female 2018 818
TX_CURR Age/Sex: 25-49 Female 2018 32,048
TX_CURR Age/Sex: 25-49 Male 2018 592
TX_CURR Age/Sex: 25-49 Male 2018 16,675
TX_CURR Age/Sex: 50+ Female 2018 42
TX_CURR Age/Sex: 50+ Female 2018 2,737
TX_CURR Age/Sex: 50+ Male 2018 88
TX_CURR Age/Sex: 50+ Male 2018 3,304
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 2,119
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 68,675
TX_CURR Sum of age/sex disaggregates 2018 2,021
TX_CURR Sum of Age/Sex disaggregations 2018 67
TX_NEW By Age/Sex: <1 2018 1
TX_NEW By Age/Sex: <1 2018 102
TX_NEW By Age/Sex: 1-9 2018 6
TX_NEW By Age/Sex: 1-9 2018 206
TX_NEW By Age/Sex: 10-14 Female 2018 15
TX_NEW By Age/Sex: 10-14 Female 2018 357
TX_NEW By Age/Sex: 10-14 Male 2018 17
TX_NEW By Age/Sex: 10-14 Male 2018 431
TX_NEW By Age/Sex: 15-19 Female 2018 7
TX_NEW By Age/Sex: 15-19 Female 2018 285
TX_NEW By Age/Sex: 15-19 Male 2018 26
TX_NEW By Age/Sex: 15-19 Male 2018 929
TX_NEW By Age/Sex: 20-24 Male 2018 67
TX_NEW By Age/Sex: 20-24 Male 2018 1,966
TX_NEW By Age/Sex: 25-49 Female 2018 32
TX_NEW By Age/Sex: 25-49 Female 2018 1,703
TX_NEW By Age/Sex: 25-49 Male 2018 95
TX_NEW By Age/Sex: 25-49 Male 2018 5,151
TX_NEW By Age/Sex: 50+ Female 2018 188
TX_NEW By Age/Sex: 50+ Male 2018 480
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 266
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 11,798
TX_NEW Sum of Age/Sex disaggregates 2018 259
TX_NEW Sum of Age/Sex disaggregates 2018 11,490
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 5,259
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 65,535
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 4,740
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 58,986
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 208
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 1,834
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 226
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 1,604
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 2,847
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 37,447
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 1,459
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 18,101
TX_PVLS Numerator: Indication: Routine 2018 4,740
TX_PVLS Numerator: Indication: Routine 2018 58,986
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 230
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 2,038
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 248
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 1,782
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 3,161
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 41,605
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 1,620
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 20,110
TX_PVLS_den Denominator: Indication: Routine 2018 5,259
TX_PVLS_den Denominator: Indication: Routine 2018 65,535
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 6
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 225
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 13
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 174
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 150
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 5,307
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 137
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 2,245
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 306
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 7,951
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 323
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 8,362
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 6
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 229
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 4
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 178
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 168
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 5,593
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 145
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 2,362
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 2,016
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 65,250
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 38
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 1,245
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 4
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 40
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 4
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 33
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 17
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 787
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 13
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 385
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 136
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 2,029
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 188
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 1,739
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2018 1,007
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2018 685
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 41,525
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 19,957
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 200
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 6,527
TX_TB_den Denominator: By Screen Result: Negative 2018 1,816
TX_TB_den Denominator: By Screen Result: Negative 2018 58,723
TX_TB_den Denominator: By Screen Result: Positive 2018 200
TX_TB_den Denominator: By Screen Result: Positive 2018 6,527
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 200
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 6,527
Cross Cutting Budget Categories and Known Amounts Total: $168,252
Gender: Gender Based Violence (GBV) $123,252
Post GBV Care
Water $45,000